CLLS
Cellectis S.A.
There isn't enough reported data to score CLLS yet.
CLLS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
CLLS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
CLLS PE Valuation
CLLS has no meaningful PE right now: it lost money over the past year.
CLLS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CLLS's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
CLLS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.66 | -$0.07 |
| Q1 2026 | -$0.68 | -$0.05 |
| Q4 2025 | -$0.68 | -$0.28 |
| Q3 2025 | -$0.35 | +$0.65 |
| Q2 2025 | -$0.59 | +$0.49 |
| Q1 2025 | -$0.63 | +$0.38 |
| Q4 2024 | -$0.40 | +$1.25 |
| Q3 2024 | -$1.00 | +$0.71 |
CLLS is still losing money, but far less than before: $0.66 per share over the past year, against $3.29 at its worst in early 2022.
CLLS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.2M | -69% |
| Q1 2026 | $5.8M | -46% |
| Q4 2025 | $10.4M | -18% |
| Q3 2025 | $35.2M | +117% |
| Q2 2025 | $16.7M | +107% |
| Q1 2025 | $10.7M | +135% |
| Q4 2024 | $12.7M | +4356% |
| Q3 2024 | $16.2M | +10352% |
CLLS's revenue fell from its 2020 peak and has held roughly level since: $5M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -487% | -430 points |
| Q1 2026 | -467% | -334 points |
| Q4 2025 | -167% | -83 points |
| Q3 2025 | 23% | +89 points |
| Q2 2025 | -57% | +156 points |
| Q1 2025 | -133% | +328 points |
| Q4 2024 | -84% | +10781 points |
| Q3 2024 | -66% | +13270 points |
CLLS's operating margin was −487% last quarter, down 430 points from the same quarter a year ago.
CLLS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.5M | -$3.9M |
| Q1 2026 | -$15.8M | +$1.7M |
| Q4 2025 | -$11M | -$9.2M |
| Q3 2025 | -$2.8M | +$3.9M |
| Q2 2025 | -$10.6M | -121% |
| Q1 2025 | -$17.6M | +$6M |
| Q4 2024 | -$1.8M | -105% |
| Q3 2024 | -$6.6M | +$10.8M |
CLLS has burned cash in almost every quarter: −$44M over the past year, against −$37M the year before.
CLLS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +120K shares |
| 1 year | +0.3% | +322K shares |
| 3 years | +81% | +45.1M shares |
| 5 years | +121% | +55.2M shares |
| Available history | +137% | +58.2M shares |
CLLS has 101M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $207,000 |
CLLS hasn't bought back shares in the past year.
CLLS Net Leverage
CLLS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CLLS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 10.3 | Oversold |
CLLS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
CLLS PE vs Healthcare Sector
CLLS has no meaningful PE right now: it lost money over the past year.
CLLS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.21 | 9.9% above |
| 20 week MA | $2.24 | 41% below |
| 50 week MA | $3.19 | 58% below |
| 100 week MA | $2.69 | 51% below |
| 200 week MA | $2.48 | 46% below |
CLLS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 46% below its 200-week average.
CLLS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.9 | $30.4 | +70% |
| 2021 | $30.4 | $8.55 | -72% |
| 2022 | $8.55 | $1.99 | -77% |
| 2023 | $1.99 | $3.08 | +55% |
| 2024 | $3.08 | $1.41 | -54% |
| 2025 | $1.41 | $4.75 | +237% |
| 2026 YTD | $4.75 | $1.33 | -72% |
CLLS's yearly returns have swung widely, from +237% in 2025 to −77% in 2022. It's down 72% so far in 2026.